SofigatranAlternative Names: MCC-977
Latest Information Update: 01 Feb 2008
At a glance
- Originator Mitsubishi Chemical
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
- 06 Jun 2006 This compound is still in active development
- 06 Dec 2004 This programme is still in active development